MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

Capmatinib is approved in the United States and Japan for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14), based on results from Phase II GEOMETRY mono-1 trial (NCT02414139). The most common adverse reactions (≥20%) were peripheral edema, nausea, fatigue, vomiting, dyspnea, decreased appetite. Here, we describe management of vomiting experienced by patients receiving capmatinib across two institutions States. In mono-1, received tablets at dose 400 mg twice daily. Dose reductions 100-mg steps minimum 200 daily required events grade ≥3. Grade 3 nausea or edema withholding until resolved ≤1, then reducing one level. 2 ≤1; ≥3 recurrent resolution ≤2 respectively, Across institutions, as first-line second-line therapy treatment NSCLC METex14 part study. Patients taking commonly mild (grade 1) edema. Peripheral was generally managed compression stockings, elevation affected limbs, and/or diuretics. At institution, referred lymphedema clinic; these lymphatic massage, prescription-grade stretching exercises. Stretching exercises stockings (20-30 mm Hg) improved 1 bilateral lower without discontinuation treatment. general, capmatinib. sometimes when while fasted. Methods treating included as-needed antiemetics premedication phenothiazine 5-HT3 antagonist. Some reported reduced taken after eating, others dosage 300 treated who successfully. some cases, our experience, food vomiting.